Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004859 · ClinicalTrials.gov registry record · Phase 3
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 589
- Enrollment target
NCT00004859: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00004859 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 589 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004859, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 589 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without thalidomide.
Primary Outcome
Survival time is defined as time from study entry to death from any cause
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2000-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Why NCT00004859 stopped before completion
NCT00004859 is an interventional study that assigns participants to a tested intervention. The registered 589 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00004859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004859 about?
NCT00004859 is a clinical study titled "Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer". This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherap...
What is the current status of trial NCT00004859?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 589 participants. The study started on 2000-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00004859?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00004859?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004859's enrollment target sits among peer trials
589 645th of 2000 higher than 1,356 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia